| 臺大學術典藏 |
2021-09-04T05:16:24Z |
Highlights
|
JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:24Z |
Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection—Authors' reply
|
Wai-Sun Wong V.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:23Z |
Improved second harmonic generation and two-photon excitation fluorescence microscopy-based quantitative assessments of liver fibrosis through auto-correction and optimal sampling
|
Hsiao C.-Y.; Teng X.; Su T.-H.; Lee P.-H.; JIA-HORNG KAO; Huang K.-W. |
| 臺大學術典藏 |
2021-09-04T05:16:23Z |
Reply to: “Sofosbuvir and the risk of kidney dysfunction”
|
Liu C.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:23Z |
Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection—authors' reply
|
Tseng T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:22Z |
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients
|
JIA-HORNG KAO; Jeng W.-J.; Ning Q.; Su T.-H.; Tseng T.-C.; Ueno Y.; Yuen M.-F. |
| 臺大學術典藏 |
2021-09-04T05:16:22Z |
Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma
|
Wu C.-H.; Liang P.-C.; Su T.-H.; Lin M.-C.; Chang Y.-H.; Shih T.T.-F.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:21Z |
Response to letter to the editor “Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy”
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:21Z |
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis
|
Su T.-H.; Peng C.-Y.; Chang S.-H.; Tseng T.-C.; Liu C.-J.; Chen C.-L.; Liu C.-H.; Yang H.-C.; Chen P.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:21Z |
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Yeh M.-L.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Chen C.-Y.; Kuo H.-T.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Liu C.-J.; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T05:16:21Z |
Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy
|
Su T.-H.; Hsu S.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:20Z |
Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study
|
Yu M.-L.; Tsai W.-L.; Chu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:20Z |
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients
|
Liu M.; Tseng T.-C.; Jun D.W.; Yeh M.-L.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung M.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO; Yang H.-I.; Nguyen M.H. |
| 臺大學術典藏 |
2021-09-04T05:16:20Z |
One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment
|
Tseng T.-C.; Choi J.; Nguyen M.H.; Peng C.-Y.; Siakavellas S.; Papatheodoridis G.; Wang C.-C.; Lim Y.-S.; Lai H.-C.; Trinh H.N.; Wong C.; Wong C.; Zhang J.; Li J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:19Z |
Response to letter to the editor “The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma”
|
Cheng Y.-M.; Tzeng I.-S.; JIA-HORNG KAO; Wang C.-C. |
| 臺大學術典藏 |
2021-09-04T05:16:19Z |
The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma
|
Wang C.-C.; Tseng K.-C.; Tzeng I.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:19Z |
Artificial intelligence in precision medicine in hepatology
|
Su T.-H.; Wu C.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:18Z |
Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma
|
Huang S.-C.; Liao S.-H.; Su T.-H.; Jeng Y.-M.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:18Z |
The metabolic profiles and body composition of lean metabolic associated fatty liver disease
|
Cheng Y.-M.; JIA-HORNG KAO; Wang C.-C. |
| 臺大學術典藏 |
2021-09-04T05:16:18Z |
Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load
|
Tseng T.-C.; Liu C.-J.; Yang W.-T.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; Chen P.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:17Z |
Reply to “Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia”
|
Yu M.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:17Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:17Z |
Highlights
|
JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:16Z |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Liu C.-J.; Dai C.-Y.; JIA-HORNG KAO; Chuang W.-L.; Lin H.-C.; Yu M.-L. |
| 臺大學術典藏 |
2019-10-14T05:52:27Z |
Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma
|
Li, Yung-Tsung;Wu, Hui-Lin;Jia-Horng Kao;Cheng, Huei-Ru;Ming-Chih Ho;Wang, Chih-Chiang;Pei-Jer Chen;Ding-Shinn Chen;Chun-Jen Liu; Li, Yung-Tsung; Wu, Hui-Lin; JIA-HORNG KAO; Cheng, Huei-Ru; MING-CHIH HO; Wang, Chih-Chiang; PEI-JER CHEN; DING-SHINN CHEN; CHUN-JEN LIU |
